Q07817 (B2CL1_HUMAN) Homo sapiens (Human)
Bcl-2-like protein 1 UniProtKBInterProSTRINGInteractive Modelling
Available Structures
118 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| STRUCTURE OF BCL-XL/BAK PEPTIDE COMPLEX, NMR, MINIMIZED AVERAGE STRUCTURE |
Heteromer Q16611; | 99.41 | ||||
| Solution structure of BCL-xL in complex with PUMA BH3 peptide |
Heteromer Q9BXH1; | 100 | ||||
| Solution structure of BCL-XL bound to P73-TAD peptide |
Heteromer O15350; | 100 | ||||
| SOLUTION STRUCTURE OF AN APOPTOSIS ACTIVATING PHOTOSWITCHABLE BAK PEPTIDE BOUND to BCL-XL |
Heteromer Q16611; | 100 | 1×33B; | |||
| COMPLEX OF BCL-XL WITH PEPTIDE FROM BAD |
Heteromer Q92934; | 100 | ||||
| TCTP contains a BH3-like domain, which instead of inhibiting, activates Bcl-xL |
Heteromer P13693; | 100 | 2×BCT; 2×NA; | |||
| Bcl-xL with mouse Bak BH3 Q75L complex |
Heteromer O08734; | 100 | 8×EDO; | |||
| Crystal structure of alpha-beta-foldamer 2c in complex with Bcl-xL |
Heteromer O43521; | 100 | 2×CL; 1×SO4; | |||
| Bcl-xL with Bak BH3 complex |
Heteromer Q16611; | 100 | 8×GOL; | |||
| Crystal structure of BCL-XL in complex with inhibitor (WEHI-539) |
Heteromer | 100 | 2×X0B; 2×EDO; 3×SO4; | |||
| Puma BH3 foldamer in complex with Bcl-xL |
Heteromer | 100 | ||||
| Crystal structure of BCL-xL in complex with computationally designed inhibitor protein |
Heteromer | 100.0 | ||||
| Crystal structure of human bcl-xL bound to trichoplax adhaerens trBak BH3 |
Heteromer A0A369S334; | 100.0 | 6×SO4; | |||
| Crystal structure of Bcl-xL in complex with HBx-BH3 motif |
Heteromer I3XMW8; | 100 | ||||
| Selective Affimers Recognize BCL-2 Family Proteins Through Non-Canonical Structural Motifs |
Heteromer | 100 | 1×SO4; | |||
| Bcl-xL complex with Beclin 1 BH3 domain T108D |
Heteromer Q14457; | 100 | 3×CL; | |||
| Solution Structure of the Complex Between BCL-xL and the p53 Core Domain determined with PRE restra… |
Heteromer P04637; | 100.0 | 1×ZN; | |||
| Crystal structure of BCL-xL in complex with computationally designed inhibitor protein |
Heteromer | 100.0 | ||||
| PROTAC6 mediated complex of VHL:EloB:EloC and Bcl-xL |
Heteromer P40337; Q15369; Q15370; | 100.0 | 1×QL8; 17×EDO; 9×GOL; 12×IOD; | |||
| Bcl-xL in complex with Bim-h3Pc-RT |
Heteromer O43521; | 100 | 6×EDO; | |||
| BimL12F in complex with Bcl-xL |
Heteromer O43521; | 100 | 1×ZN; | |||
| Bcl-xL complex with Beclin 1 BH3 domain T108pThr |
Heteromer Q14457; | 100 | ||||
| Crystal structure of alpha-beta foldamer 4c in complex with Bcl-xL |
Heteromer O43521; | 100 | ||||
| Structure of the Bcl-XL:Beclin 1 complex |
Heteromer Q14457; | 100 | ||||
| Structure of Bcl-xL bound to BimSAHB |
Heteromer O43521; | 100 | 14×GOL; | |||
| Structure of Bcl-xL bound to BimLOCK |
Heteromer O43521; | 100 | 2×GOL; | |||
| Complex of Bcl-xL with its BH3 domain |
Heteromer | 100 | 1×CA; 1×EPE; 2×EDO; | |||
| Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival protei… |
Heteromer Q96LC9; | 100.0 | ||||
| Crystallographic structure of BCL-xL domain-swapped dimer in complex with PUMA BH3 peptide at 2.9A … |
Heteromer Q9BXH1; | 100.0 | ||||
| E3:PROTAC:target ternary complex structure (VCB/753b/BCL-xL) |
Heteromer P40337; Q15369; Q15370; | 100.0 | 1×CAD; 2×GOL; 1×YF8; | |||
| Bcl-xL in complex with HBx BH3 delta C peptide |
Heteromer P0C689; | 100 | ||||
| Solution structure of the Bcl-xL/Beclin-1 complex |
Heteromer Q14457; | 100 | ||||
| Crystal structure of Bcl-xL in complex with BIM BH3 domain |
Heteromer O43521; | 100.0 | ||||
| Bcl-xL bound to alpha beta Puma BH3 peptide 5 |
Heteromer Q9BXH1; | 100 | 15×CD; 2×EDO; | |||
| Crystal structure of Bcl-xL in complex with BID BH3 domain |
Heteromer P55957; | 100.0 | 1×IMD; | |||
| Bim BH3 peptide in complex with Bcl-xL |
Heteromer O43521; | 100 | ||||
| Crystal structure of human SOUL BH3 domain in complex with Bcl-xL |
Heteromer Q9Y5Z4; | 100 | 1×SO4; | |||
| Crystal structure of Bcl-xl bound to BIM-MM |
Heteromer O43521; | 100 | ||||
| Crystal structure of Bcl-xL in complex with the BaxBH3 domain |
Heteromer Q07812; | 100.0 | ||||
| Structure of human Bcl-2 in complex with PUMA BH3 peptide |
Heteromer P10415; Q9BXH1; | 100 | ||||
| Affimer:BclxL |
Heteromer | 100 | ||||
| Bcl-2 complex with Beclin 1 T108D BH3 domain |
Heteromer P10415; Q14457; | 100.0 | ||||
| Bcl-2 alpha beta-1 LINEAR complex |
Heteromer O43521; P10415; | 100.0 | ||||
| Bcl-2 alpha beta-1 complex |
Heteromer O43521; P10415; | 100.0 | ||||
| Structural basis of the specificity and interaction mechanism of Bmf binding to pro-survival protei… |
Heteromer P10415; Q96LC9; | 100.0 | ||||
| Crystal structure of Bcl-xL hexamer | homo-6-mer | 100.0 | 6×GOL; | |||
| Crystal structure of Bcl-xL in complex with benzoylurea compound (42) | homo-4-mer | 100 | 4×X0R; 12×SO4; 20×EDO; | |||
| Crystal structure of BCL-XL bound to compound 7: (R)-3-(Benzylthio)-2-(3-(4-chloro-[1,1':2',1'':3''… | homo-2-mer | 100 | 2×QHV; 1×EDO; | |||
| Bcl-XL 3D Domain Swapped Dimer | homo-2-mer | 100.0 | ||||
| Crystal structure of Bcl-xL in complex with benzoylurea compound (39b) | homo-2-mer | 100 | 2×X0D; 7×SO4; 12×EDO; | |||
| alpha/beta foldamer in complex with Bcl-xL | homo-2-mer | 100 | 11×EDO; | |||
| Crystal structure of BCL-XL bound to compound 8: (R)-3-(Benzylthio)-2-(3-(2-((4'-chloro-[1,1'-biphe… | homo-2-mer | 100 | 2×XOY; 3×SO4; 9×EDO; | |||
| CRYSTAL STRUCTURE OF BCL-XL IN COMPLEX WITH COMPOUND 1620116, CRYSTAL FORM 2 | homo-2-mer | 100 | 2×V9S; | |||
| Crystal structure of BCL-XL bound to compound 13: (R)-2-(3-([1,1'-Biphenyl]-4-carbonyl)-3-(4-methyl… | homo-2-mer | 100 | 2×QHP; 2×SO4; 1×EDO; | |||
| Crystal structure of BCL-XL bound to compound 2: (2R)-3-(Benzylsulfanyl)-2-({[(4-methylphenyl)methy… | homo-2-mer | 100 | 2×XOU; 3×SO4; 11×EDO; | |||
| Crystal structure of BCL-XL in complex with COMPOUND 1620116, CRYSTAL FORM 1 | homo-2-mer | 100 | 2×V9S; | |||
| Crystal structure analysis of cp3 bound BCLxl | homo-2-mer | 100 | 2×GOL; 2×JJ9; | |||
| Bcl-xL in complex with inhibitor (Compound 10) | homo-2-mer | 100 | 2×38H; 7×EDO; 1×ACT; | |||
| Crystal structure of BCL-XL in complex with W1191542 | homo-2-mer | 100 | 2×X0J; 11×EDO; 1×CL; | |||
| Crystal structure of BCL-XL bound to compound 15: (R)-2-(3-(2-((4'-Chloro-[1,1'-biphenyl]-2-yl)meth… | homo-2-mer | 100 | 1×EDO; 1×SO4; 2×QHJ; | |||
| Crystal structure of BCL-XL bound to compound 12: (R)-2-(3-([1,1'-Biphenyl]-4-carbonyl)-3-(4-methyl… | homo-2-mer | 100 | 5×SO4; 2×EDO; 2×QHS; | |||
| Discovery of a Potent and Selective BCL-XL Inhibitor That Demonstrates Thrombocytopenia and Inhibit… | homo-2-mer | 100.0 | 2×3CQ; | |||
| BCL-XL in a complex with a covalent small molecule inhibitor | homo-2-mer | 100.0 | 2×KBH; 1×BR; | |||
| Crystal structure of Bcl-xL in complex with compound 10 | homo-2-mer | 100.0 | 2×LC6; 2×PO4; | |||
| NMR STRUCTURE OF BCL-XL, AN INHIBITOR OF PROGRAMMED CELL DEATH, MINIMIZED AVERAGE STRUCTURE | monomer | 99.52 | ||||
| Solution Structure of the Anti-apoptotic Protein Bcl-xL in Complex with "SAR by NMR" Ligands | monomer | 100 | 1×4FC; 1×TN1; | |||
| Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based l… | monomer | 100 | 1×N3B; | |||
| Solution Structure of BCL-xL in its p53-bound conformation determined with selective isotope labell… | monomer | 100 | ||||
| Solution structure of BCL-xL determined with selective isotope labelling of I,L,V sidechains | monomer | 100 | ||||
| Solution structure of the anti-apoptotic protein Bcl-xL complexed with an acyl-sulfonamide-based li… | monomer | 100 | 1×43B; | |||
| Solution structure of BCL-xL containing the alpha1-alpha2 disordered loop determined with selective… | monomer | 100 | ||||
| Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based l… | monomer | 100 | 1×43B; | |||
| Solution structure of a Bcl-xL S62E mutant | monomer | 99.52 | ||||
| NMR STRUCTURE of Bcl-XL | monomer | 100 | ||||
| Crystal structure of BCL-XL in complex with a benzothiazole-based inhibitor | monomer | 95.65 | 1×XZM; | |||
| Crystal Structure of Bcl-xL bound to BM903 | monomer | 100.0 | 1×03B; 4×ZN; 3×ACT; | |||
| Crystal structure of p53/BCL-xL fusion complex | monomer | 100.0 | 1×ZN; | |||
| The Crystal Structure of p53/BCL-xL fusion complex from Biortus. | monomer | 100.0 | 1×ZN; | |||
| Crystal Structure of Bcl-xL bound to BM501 | monomer | 100.0 | 1×B50; 4×GOL; | |||
| Structure of human Bcl-2 in complex with ABT-263 | monomer | 100 | 1×1XJ; | |||
| Human Bcl-XL containing a Phe to Leu mutation at position 146 | monomer | 99.3 | ||||
| Crystal structure of BCL-XL in complex with inhibitor (Compound 3) | monomer | 100.0 | 1×H0Y; 1×SO4; 5×EDO; | |||
| The Crystal Structure of human Bcl-2-like protein 1 from Biortus | monomer | 100.0 | 3×SO4; | |||
| Structure of Human Bcl-XL at 1.95 Angstroms | monomer | 100.0 | ||||
| X-RAY STRUCTURE OF BCL-XL, AN INHIBITOR OF PROGRAMMED CELL DEATH | monomer | 100.0 | ||||
| Human Bcl-XL containing an Ala to Leu mutation at position 142 | monomer | 99.3 | ||||
| Crystal structure of Bcl-xL in complex with inhibitor (Compound 2). | monomer | 100.0 | 1×H1I; | |||
| Crystal structure of BCL-XL in complex with inhibitor (Compound 6) | monomer | 100.0 | 1×X8U; | |||
| Human Bcl-XL containing a Phe to Trp mutation at position 97 | monomer | 99.3 | ||||
| Crystal structure of Bcl-xL in complex with tetrahydroisoquinoline-pyridine based inhibitors | monomer | 95.83 | 1×RQ7; | |||
| Crystal structure of Bcl-xL in complex with a small molecule inhibitor | monomer | 95.83 | 1×A1AFG; 2×CD; | |||
| Crystal structure of cp1 bound BCLxl | monomer | 100 | 1×JFF; | |||
| Crystal structure of Bcl-Xl complex with 4-(5-butyl-3-(hydroxymethyl)-1-phenyl-1h-pyrazol-4-yl)-3-(… | monomer | 100.0 | 1×0Q5; 1×IMD; | |||
| Human Bcl-XL containing a Glu to Leu mutation at position 92 | monomer | 99.3 | ||||
| Human Bcl-xL containing a Trp to Ala mutation at position 137 | monomer | 99.29 | ||||
| Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based l… | monomer | 100 | 1×LIW; | |||
| Solution structure of the anti-apoptotic protein Bcl-xL in complex with an acyl-sulfonamide-based l… | monomer | 100 | 1×LI0; | |||
| Structure of human Bcl-2 in complex with fragment/ABT-263 hybrid | monomer | 100 | 1×J1T; | |||
| Crystal structure of Bcl-xL in complex with a Quinazoline sulfonamide inhibitor | monomer | 100.0 | 1×HI0; 1×CL; 1×GOL; | |||
| Crystal structure of Bcl-xL in complex with ABT-737 | monomer | 100.0 | 1×CL; 1×N3C; 1×GOL; | |||
| Structure of human Bcl-2 in complex with THIQ-phenyl pyrazole compound | monomer | 100 | 1×J1Q; 1×ACT; | |||
| Structure of human Bcl-2 in complex with analogue of ABT-737 | monomer | 100 | 1×J1H; | |||
| anti-apoptotic protein BCL-2-M12 | monomer | 100 | 1×IQ8; | |||
| Crystal structure of Bcl-2 in complex with the novel orally active inhibitor S55746 | monomer | 80.0 | 1×F3Q; | |||
| Structure of the transmembrane helix of BclxL in phospholipid nanodiscs | monomer | 100 | ||||
| Structure of the C-terminal domain of BCL-XL in membrane | monomer | 100 | ||||
| crystal structure of BCL-2 with venetoclax | monomer | 100.0 | 1×LBM; 1×2PE; | |||
| crystal structure of BCL-2 F104L mutation with venetoclax | monomer | 100.0 | 1×LBM; 4×PEG; | |||
| Human Bcl-2 (G101V Mutant)/Bcl-xL Chimera Fused to Maltose-Binding Protein | monomer | 100.0 | ||||
| crystal structure of BCL-2 G101A mutation with venetoclax | monomer | 100.0 | 1×LBM; 3×PEG; | |||
| crystal structure of BCL-2 G101V mutation with S55746 | monomer | 100.0 | 1×F3Q; | |||
| Human Bcl-2/Bcl-xL Chimera Fused to Maltose-Binding Protein | monomer | 100.0 | ||||
| Crystal Structure of human Bcl-2 in complex with a small molecule inhibitor targeting Bcl-2 BH3 dom… | monomer | 100.0 | 1×1E9; | |||
| Human Bcl-2/Bcl-xL Chimera Fused to MBP in Complex with Inhibitor S55746 | monomer | 100.0 | 1×F3Q; 1×PEG; | |||
| crystal structure of BCL-2 G101V mutation with venetoclax | monomer | 100.0 | 1×LBM; 2×PEG; 1×CL; | |||
| Human Bcl-2 (G101V Mutant)/Bcl-xL Chimera Fused to MBP in Complex with Inhibitor S55746 | monomer | 100.0 | 1×F3Q; 1×PEG; | |||
| Bcl-2-xL complexed with compound 35 | monomer | 100 | 1×ULL; | |||
| HUMAN BCL-2 WITH PHENYLACYLSULFONAMIDE INHIBITOR | monomer | 100 | 1×398; | |||
2 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 4qnq.5.A | monomer | 0.69 | 1×1XJ; | 97.85 | ||
| 2b48.1.A | monomer | 0.50 | 100.00 | |||
1 SWISS-MODEL model built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 3 | 4qnq.5.A | monomer | 0.67 | 84.75 | |||